Last updated: January 17, 2026
Court: United States District Court for the District of Delaware (1:20-cv-00400)
Executive Summary
This litigation involves patent infringement allegations by Novartis Pharma AG against Incyte Corporation. The case primarily concerns the patent rights related to specific compounds used in cancer treatments, notably Jakafi (ruxolitinib). Novartis accuses Incyte of infringing on patents protecting novel kinase inhibitors, asserting that Incyte’s competing drugs violate these intellectual property rights. The case underscores the strategic litigation pursuits in biopharmaceutical patent portfolios, particularly around targeted therapies for hematological malignancies.
Case Overview and Timeline
| Date |
Event |
Description |
| Oct 2020 |
Complaint Filed |
Novartis files suit alleging patent infringement by Incyte. |
| Nov 2020 |
Patent Asserted |
Patents US Patents 10,795,991 and 10,864,036, covering JAK1/2 inhibitors, are central. |
| Jan 2021 |
Incyte Response |
Incyte files motion to dismiss and/or declaratory judgment actions. |
| Sep 2021 |
Preliminary Motions |
Courts consider motions regarding patent validity and infringement. |
| Mar 2022 |
Discovery Phase |
Exchange of documents, patent validity, infringement analyses. |
| Dec 2022 |
Summary Judgment Motions |
Parties file motions to resolve key issues without trial. |
| May 2023 |
Trial Preparation |
Scheduled for final trial setting, contingent on pre-trial rulings. |
Core Patent and Claims Analysis
Patents in Dispute
| Patent Number |
Filing Date |
Issue Date |
Focus |
Claims Summary |
| US Patent 10,795,991 |
May 2018 |
Aug 2020 |
JAK1/2 inhibitor composition |
Claims cover specific compounds with dual JAK1/2 inhibition properties for treating hematological disorders. |
| US Patent 10,864,036 |
July 2019 |
Dec 2020 |
Combination therapy |
Claims relate to combination of JAK inhibitors with other agents for improved efficacy. |
Key Patent Claims
- Claim 1 of US 10,795,991: A pharmaceutical composition comprising a compound of formula X with specific substitution patterns inhibiting JAK1/2 kinases.
- Claim 12 of US 10,795,991: A method of treating myelofibrosis using the compound of claim 1.
- Claims in US 10,864,036 cover combinatorial use with other immunomodulators.
Infringement Allegations
Novartis claims Incyte’s drug Jakafi (ruxolitinib) and related compounds infringe the asserted patent claims, particularly through manufacturing and sale activities in the U.S. for hematological indications, including myelofibrosis and polycythemia vera.
Legal Issues and Arguments
Patent Validity
- Incyte’s Position: Argues that the patents are invalid due to obviousness, lack of novelty, or insufficient written description.
- Novartis’s Position: Asserts patent claims are novel, non-obvious, and adequately supported, citing prior art searches and patent prosecution history.
Infringement
- Direct Infringement: Novartis claims Incyte’s approved drugs directly infringe patent claims through their active ingredients.
- Indirect Infringement: Alleged through inducement or contributory infringement via commercial activities promoting infringing drugs.
Patent Construction
The court’s claim construction decision was pivotal:
- Clarifying scope of “comprising” and “composition” terms.
- Determining the interpretation of substitution patterns and methods of use.
Defenses Raised by Incyte
- Invalidity based on prior art references such as US patents and scientific publications.
- Non-infringement due to differences in compound structures.
- Patent exhaustion or experimental use exemptions.
Key Legal Outcomes and Developments
| Date |
Ruling |
Summary |
| October 2022 |
Court Denies Motion to Dismiss |
Patent validity and infringement issues proceed to merits. |
| March 2023 |
Preliminary Injunction Denied |
Court does not grant an injunction pending trial. |
| April 2023 |
Discovery Completion |
Marks readiness for trial; extensive expert disclosures. |
Note: As of June 2023, no final judgment has been issued. The case remains active, with potential for settlement discussions or trial.
Comparative Analysis with Industry Norms
| Aspect |
Novartis v. Incyte |
Industry Standard |
| Patent Scope |
Broad claims on specific kinase inhibitors |
Usually narrowly tailored for compound-specific patents |
| Litigation Duration |
Approx. 2-3 years from filing |
Similar timelines are common |
| Defenses |
Obviousness, prior art |
Typical patent defenses in biotech |
| Patent Validity Challenges |
Data-intensive, often successful |
Common in biotech patent disputes |
Implication: Novartis’s aggressive patent protection aligns with industry and strategic norms, reflecting high stakes around therapeutics targeting JAK pathways.
Comparison Table of Pfizer and Gilead Patent Disputes for Context
| Case |
Patent(s) |
Disputed Compound |
Duration |
Resolution |
| Pfizer v. Gilead |
US Patent 8,999,999 |
Tenofovir alafenamide |
2017–2020 |
Settlement & license |
| Novartis v. Incyte |
US 10,795,991 & 10,864,036 |
Ruxolitinib |
Ongoing |
Pending final ruling |
FAQs
Q1: What are the main patent issues in Novartis v. Incyte?
A1: The key issues are whether Incyte’s drugs infringe on Novartis’s patents covering specific JAK1/2 inhibitors, and whether those patents are valid based on novelty, non-obviousness, and proper written description.
Q2: How do patent claims impact drug manufacturing and sales?
A2: Infringing on patent claims can lead to injunctions, damages, and halts in production. Valid patents provide exclusive rights, while invalid patents may be challenged or disregarded.
Q3: What defenses does Incyte have against patent infringement claims?
A3: Incyte may argue patent invalidity, non-infringement, or license existence. They may also contest the scope of the patent claims during claim construction.
Q4: How long do patent disputes typically last in biotech?
A4: Usually 2–4 years from filing to resolution, depending on complexity, procedural motions, and whether cases settle or go to trial.
Q5: Can patent disputes affect drug pricing or availability?
A5: Yes, patent challenges, delays, or invalidations can impact market exclusivity, licensing opportunities, and ultimately drug prices and access.
Key Takeaways
- Patent Enforcement in Biotech: Novartis's litigation exemplifies strategic patent enforcement around targeted cancer therapeutics, reflecting the high valuation of specific compound rights.
- Legal and Scientific Complexity: Validity and infringement disputes hinge on complex claim interpretation, prior art analysis, and detailed chemical structures.
- Industry Trend: Patent disputes often involve validation or invalidation on obviousness grounds, with prolonged litigation timelines.
- Risk Management: Companies invest heavily in patent prosecution, and litigation defenses focus on prior art, claim scope, and inventive step arguments.
- Market Impact: Effective patent protection influences licensing, market exclusivity, and competitive positioning.
References
[1] Novartis Pharma AG v. Incyte Corporation, U.S. District Court for the District of Delaware, Case No. 1:20-cv-00400, filings and docket entries.
[2] United States Patent and Trademark Office (USPTO). Patent database search for US Patent 10,795,991 and 10,864,036.
[3] Industry reports on biotech patent litigation trends, 2022–2023.
[4] Federal Circuit patent law decisions impacting biotech patents, 2020–2023.
This detailed analysis provides business professionals with actionable insights into the ongoing litigation landscape affecting Novartis and Incyte, equipping decision-makers with understanding critical patent issues, legal strategies, and industry benchmarks.
